share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  08/19 06:08

Moomoo AI 已提取核心訊息

Cingulate Inc., a company listed on the Nasdaq Capital Market, has announced an increase in the maximum aggregate offering price of its common stock under the At The Market Offering Agreement with H.C. Wainwright & Co. The increase, reported on August 19, 2024, raises the offering from $8,470,000 to $11,326,658, with a prospectus supplement filed for an additional $2,856,658 in shares. Prior to this, Cingulate Inc. had sold shares totaling $8,468,402.99 under the same agreement. Additionally, on August 15, 2024, Cingulate Inc. disclosed the issuance of a European patent for CTx-1301, a treatment for Attention Deficit Hyperactivity Disorder (ADHD), which will extend to up to 30 European territories, including the UK. The patent was granted on August 14, 2024, as EP Patent No. 3261625.
Cingulate Inc., a company listed on the Nasdaq Capital Market, has announced an increase in the maximum aggregate offering price of its common stock under the At The Market Offering Agreement with H.C. Wainwright & Co. The increase, reported on August 19, 2024, raises the offering from $8,470,000 to $11,326,658, with a prospectus supplement filed for an additional $2,856,658 in shares. Prior to this, Cingulate Inc. had sold shares totaling $8,468,402.99 under the same agreement. Additionally, on August 15, 2024, Cingulate Inc. disclosed the issuance of a European patent for CTx-1301, a treatment for Attention Deficit Hyperactivity Disorder (ADHD), which will extend to up to 30 European territories, including the UK. The patent was granted on August 14, 2024, as EP Patent No. 3261625.
納斯達克資本市場上市公司Cingulate公司宣佈,在與H.C. Wainwright合作的在市場發行協議下,其普通股最高總髮行價已從847萬美元上調到1132.6658萬美元。該調整於2024年8月19日公佈,附加招股說明書募集所得額外285.6658萬美元的股票。在此之前,Cingulate公司已根據該協議出售了總計847萬美元的股票。此外,2024年8月15日,Cingulate公司披露了CTx-1301的歐洲專利發行情況,CTx-1301是用於治療注意力缺陷多動障礙(ADHD)的藥物,在包括英國在內的30個歐洲領土內有效。該專利於2024年8月14日授權,編爲EP專利號3261625。
納斯達克資本市場上市公司Cingulate公司宣佈,在與H.C. Wainwright合作的在市場發行協議下,其普通股最高總髮行價已從847萬美元上調到1132.6658萬美元。該調整於2024年8月19日公佈,附加招股說明書募集所得額外285.6658萬美元的股票。在此之前,Cingulate公司已根據該協議出售了總計847萬美元的股票。此外,2024年8月15日,Cingulate公司披露了CTx-1301的歐洲專利發行情況,CTx-1301是用於治療注意力缺陷多動障礙(ADHD)的藥物,在包括英國在內的30個歐洲領土內有效。該專利於2024年8月14日授權,編爲EP專利號3261625。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息